Serina Therapeutics, Inc. Amortization of Debt Issuance Costs
Serina Therapeutics, Inc. (SER) reported Amortization of Debt Issuance Costs of $141.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-13
- Serina Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $77.00K.
- Serina Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $64.00K.
- Serina Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $58.00K, a 625.00% increase year-over-year.
- Serina Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. amortization of debt issuance costs for fiscal 2025 was $58.00K, a 83.19% decline from fiscal 2024.
- Serina Therapeutics, Inc. amortization of debt issuance costs for fiscal 2024 was $345.00K.
- Serina Therapeutics, Inc. amortization of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Serina Therapeutics, Inc. amortization of debt issuance costs for fiscal 2022 was $3.14M, a 181.60% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 9 month as first filed | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $141.00K 10-Q · filed 2026-08-13 | $199.00K derived: sum of 3 quarters · filed 2026-08-13 | $199.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $64.00K 10-Q · filed 2026-05-14 | $122.00K derived: sum of 2 quarters · filed 2026-05-14 | $122.00K derived: sum of 3 quarters · filed 2026-05-14 | $122.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $58.00K derived: sum of 2 quarters · filed 2026-03-25 | $58.00K derived: sum of 3 quarters · filed 2026-08-13 | $58.00K 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-13 | $8.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $8.00K derived: sum of 3 quarters · filed 2026-08-13 | $16.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $8.00K derived: sum of 2 quarters · filed 2026-05-14 | $16.00K derived: sum of 3 quarters · filed 2026-05-14 | $323.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $16.00K derived: sum of 2 quarters · filed 2026-03-25 | $323.00K derived: sum of 3 quarters · filed 2026-03-25 | $345.00K 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $315.00K derived: sum of 2 quarters · filed 2025-11-13 | $337.00K 10-Q · filed 2025-11-13 | $337.00K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $329.00K 10-Q · filed 2025-08-11 | $329.00K derived: sum of 3 quarters · filed 2025-08-11 | -$1.65M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $22.00K 10-Q · filed 2025-05-08 | $22.00K derived: sum of 2 quarters · filed 2025-05-08 | -$1.95M derived: sum of 3 quarters · filed 2025-05-08 | -$1.03M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$1.98M derived: sum of 2 quarters · filed 2025-03-24 | -$1.06M derived: sum of 3 quarters · filed 2025-03-24 | $0.00 10-K · filed 2025-03-24 | $5.29M 10-K · filed 2024-03-22 | |
| 2023-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.06M derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $5.17M 10-Q · filed 2023-11-14 | $916.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.98M 10-Q · filed 2023-08-14 | $2.89M derived: sum of 3 quarters · filed 2024-03-22 | $3.76M derived: sum of 4 quarters · filed 2024-03-22 | ||
| 2023-03-31 | $1.06M 10-Q · filed 2023-05-12 | $1.97M derived: sum of 2 quarters · filed 2024-03-22 | $2.84M derived: sum of 3 quarters · filed 2024-03-22 | $3.65M derived: sum of 4 quarters · filed 2024-03-22 | ||
| 2022-12-31 | $916.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $1.78M derived: sum of 2 quarters · filed 2024-03-22 | $2.59M derived: sum of 3 quarters · filed 2024-03-22 | $3.14M 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $866.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.68M derived: sum of 2 quarters · filed 2023-11-14 | $2.22M 10-Q · filed 2023-11-14 | $2.52M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $811.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.35M 10-Q · filed 2023-08-14 | $1.65M derived: sum of 3 quarters · filed 2023-08-14 | $1.93M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $544.00K 10-Q · filed 2023-05-12 | $838.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.12M derived: sum of 3 quarters · filed 2023-05-12 | $1.39M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $577.00K derived: sum of 2 quarters · filed 2023-03-31 | $847.00K derived: sum of 3 quarters · filed 2023-03-31 | $1.11M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $553.00K derived: sum of 2 quarters · filed 2022-11-10 | $820.00K 10-Q · filed 2022-11-10 | $1.03M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $537.00K 10-Q · filed 2022-08-12 | $747.00K derived: sum of 3 quarters · filed 2022-08-12 | $894.00K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $267.00K 10-Q · filed 2022-05-13 | $477.00K derived: sum of 2 quarters · filed 2022-05-13 | $624.00K derived: sum of 3 quarters · filed 2022-05-13 | $707.00K derived: sum of 4 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $357.00K derived: sum of 2 quarters · filed 2022-03-29 | $440.00K derived: sum of 3 quarters · filed 2022-03-29 | $487.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $230.00K derived: sum of 2 quarters · filed 2021-11-12 | $277.00K 10-Q · filed 2021-11-12 | $314.00K derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $130.00K 10-Q · filed 2021-08-13 | $167.00K derived: sum of 3 quarters · filed 2021-08-13 | |||
| 2020-03-31 | $47.00K 10-Q · filed 2021-05-17 | $84.00K derived: sum of 2 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $54.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $17.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |